Opinion|Videos|August 1, 2024
Unmet Needs in IPF Landscape
Author(s)Justin Oldham, MD, MS
Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the current unmet needs in IPF treatment and why is it necessary to develop new pharmacotherapies for this disease?
- What biomarkers are currently used for the diagnosis of IPF?
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.
Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Early Signs of Success for Missouri’s New Notification of Pregnancy
4
Dupilumab Eases Chronic Hand Eczema With or Without Atopic Background
5